Roivant Sciences (ROIV) Expected to Announce Earnings on Friday

Roivant Sciences (NASDAQ:ROIV) is anticipated to issue its Q3 2026 results before the market opens on Friday, February 6th. Analysts expect the company to announce earnings of ($0.27) per share and revenue of $6.1390 million for the quarter. Individuals may visit the the company’s upcoming Q3 2026 earning results page for the latest details on the call scheduled for Friday, February 6, 2026 at 8:00 AM ET.

Roivant Sciences Stock Up 0.1%

NASDAQ:ROIV opened at $21.97 on Wednesday. The stock has a market capitalization of $15.28 billion, a price-to-earnings ratio of -39.23 and a beta of 1.22. Roivant Sciences has a 52 week low of $8.73 and a 52 week high of $23.91. The firm has a 50 day moving average of $21.95 and a 200 day moving average of $17.62.

Insider Transactions at Roivant Sciences

In related news, CFO Richard Pulik sold 406,731 shares of the stock in a transaction that occurred on Tuesday, December 23rd. The shares were sold at an average price of $22.43, for a total value of $9,122,976.33. Following the transaction, the chief financial officer owned 239,413 shares in the company, valued at approximately $5,370,033.59. This represents a 62.95% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Vivek Ramaswamy sold 1,975,858 shares of the firm’s stock in a transaction that occurred on Friday, December 12th. The stock was sold at an average price of $21.96, for a total transaction of $43,389,841.68. Following the transaction, the insider directly owned 36,350,621 shares of the company’s stock, valued at $798,259,637.16. This represents a 5.16% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 12,332,392 shares of company stock valued at $266,393,645. 10.80% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the business. Allworth Financial LP boosted its holdings in Roivant Sciences by 48.1% in the third quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock valued at $27,000 after purchasing an additional 583 shares during the last quarter. Osaic Holdings Inc. lifted its holdings in shares of Roivant Sciences by 204.2% in the 2nd quarter. Osaic Holdings Inc. now owns 5,783 shares of the company’s stock valued at $65,000 after buying an additional 3,882 shares during the period. Orion Porfolio Solutions LLC purchased a new stake in shares of Roivant Sciences in the second quarter worth about $117,000. Russell Investments Group Ltd. grew its holdings in Roivant Sciences by 149.9% during the second quarter. Russell Investments Group Ltd. now owns 11,467 shares of the company’s stock worth $129,000 after acquiring an additional 6,879 shares during the period. Finally, Danske Bank A S purchased a new position in Roivant Sciences during the third quarter valued at approximately $138,000. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently commented on ROIV shares. Weiss Ratings reiterated a “hold (c-)” rating on shares of Roivant Sciences in a report on Thursday, January 22nd. HC Wainwright upped their target price on Roivant Sciences from $23.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, December 12th. Leerink Partners raised their price target on Roivant Sciences from $29.00 to $32.00 and gave the stock an “outperform” rating in a report on Monday, December 15th. Wall Street Zen upgraded Roivant Sciences from a “strong sell” rating to a “hold” rating in a research note on Sunday, November 16th. Finally, Guggenheim restated a “buy” rating and set a $28.00 price objective on shares of Roivant Sciences in a report on Thursday, December 18th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, Roivant Sciences presently has an average rating of “Moderate Buy” and a consensus price target of $25.19.

About Roivant Sciences

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.